vivi
Uploaded by
29 SLIDES
450 VUES
300LIKES

Activity Goals

DESCRIPTION

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities. Activity Goals. Extended Follow-up CLL8 (GCLLSG). CLL5 Protocol: Overall Survival. PFS in Patients > 70 y: Across Treatment Regimens.

1 / 29

Télécharger la présentation

Activity Goals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Individualizing Therapy for Patients With CLL in the Community Practice Setting:Focus on Age and Comorbidities

  2. Activity Goals

  3. Extended Follow-up CLL8 (GCLLSG)

  4. CLL5 Protocol: Overall Survival

  5. PFS in Patients > 70 y: Across Treatment Regimens

  6. Fludarabine (F) vs Chlorambucil (Ch) by Age Group < or > 65 y

  7. PFS: Ch vs Bendamustine (B) in Untreated CLL

  8. Ch + Rituximab (R) in Symptomatic, Previously Untreated CLL

  9. Ch + R in Symptomatic, Previously Untreated CLL

  10. Targeting of BCR Signaling With Ibrutinib

  11. Phase 2 (PCYC-1102-CA) in CLL/SLL

  12. Phase 2: Best Response by Risk Features

  13. Phase 2: PFS

  14. Phase 2: PFS by Prognostic Factors

  15. Ibrutinib and Rituximab (IR) in High-Risk CLL

  16. Transient Lymphocytosis on IR in High-Risk CLL

  17. Lymph Node Responses Assessed by CT (31 Evaluable Patients)

  18. Idelalisib + Rituximab in Frontline CLL

  19. Nodal Response: Idelalisib + Rituximab

  20. Response: Idelalisib + Rituximab

  21. PFS: Idelalisib + Rituximab

  22. Conclusions

  23. Abbreviations

  24. Abbreviations (cont)

  25. References

  26. References (cont)

  27. References (cont)

  28. References (cont)

  29. References (cont)

More Related